Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in EGPA (BITE)
NCT03010436Phase 2Unknown
- Sponsor
- National Jewish Health
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by National Jewish Health. Status: unknown.
02
Drugs
benralizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT03010436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010436.